The linked FDA records identify Tdm Co., Ltd. as applicant on three premarket notifications, all decided as substantially equivalent (SESE) in October 2026. The filings list a Gwangju, Korea address and Jungwook Choi as contact. Two devices fall under product code HRS, the bone fixation plate category, and one under NKB, the thoracolumbosacral pedicle screw category. Each record carries a summary statement, and none was reviewed through the third-party pathway. [1][2][3]

Documented clearances and their dates

K263269 covers Park's Pectus System under product code HRS. The FDA received the submission on September 18, 2026, and decided it on October 15, 2026, with a decision of substantially equivalent and a clearance type listed as Special. The device is assigned to the orthopedic advisory committee and a summary statement is noted. [1]

K261611 covers the TDM Large Bone Plate and Screw System, also under HRS. It was received May 15, 2026, and decided October 2, 2026, as substantially equivalent with a Special clearance type. The monthly premarket listing file carries the same applicant, contact, address, dates, decision code and product code for this submission. [2][9]

K263062 covers the NOVIX Pedicle Screw System under product code NKB, regulation number 888.3070. It was received September 1, 2026, and decided October 1, 2026, as substantially equivalent with a Special clearance type. The advisory committee is orthopedic and a summary statement is noted. [3]

Product scope as described in the filings

The two HRS filings sit in the bone fixation plate category, which the FDA classifies as a Class II device under regulation 888.3030. The Park's Pectus System and the TDM Large Bone Plate and Screw System are the two named devices in that category. The filings do not describe component lists, materials or intended clinical use beyond the device names and classifications. [1][2]

The NOVIX Pedicle Screw System is filed under the thoracolumbosacral pedicle screw category, regulation 888.3070, also Class II. This is the only supplied filing from Tdm Co., Ltd. in that product code. [3]

Applicant identity and filing address

All three records name Tdm Co., Ltd. as applicant, with the contact Jungwook Choi and an address at 69, Cheomdan Venture So-Ro, 37 Beon-Gil, Buk-Gu, Gwangju, postal code 61003, country code KR. This is the address recorded on the FDA submissions; the filings do not state a corporate headquarters, ownership structure or parent company. [1][2][3]

The public documents do not identify a website, brand family, distributor, customer or manufacturing site for Tdm Co., Ltd. beyond the applicant name and filing address. Any such details remain unknown from these records. [1][2][3]

How the collection is bounded

The supplied portfolio contains three linked 510(k) records, all with a SESE decision, and the sample of three records shows the same three SESE decisions. These counts describe the supplied filings as of the snapshot date and are not a measure of total company sales, total portfolio or safety performance. No recall records appear in the supplied sample. [1][2][3]